Switch theme
Sign up to access all valuation multiples
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.
1965
527
LTM Revenue n/a
LTM EBITDA n/a
$233M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adimmune has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Adimmune achieved revenue of $47.0M and an EBITDA of -$2.5M.
Adimmune expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adimmune valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $53.9M | $47.0M | XXX | XXX | XXX |
| Gross Profit | $26.9M | $12.4M | XXX | XXX | XXX |
| Gross Margin | 50% | 26% | XXX | XXX | XXX |
| EBITDA | -$15.5M | -$2.5M | XXX | XXX | XXX |
| EBITDA Margin | -29% | -5% | XXX | XXX | XXX |
| Net Profit | $8.8M | -$19.3M | XXX | XXX | XXX |
| Net Margin | 16% | -41% | XXX | XXX | XXX |
| Net Debt | n/a | $18.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Adimmune's stock price is TWD 18 (or $1).
Adimmune has current market cap of TWD 7.6B (or $229M), and EV of TWD 7.7B (or $233M).
See Adimmune trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $233M | $229M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Adimmune has market cap of $229M and EV of $233M.
Adimmune's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Adimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Adimmune and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $233M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | -91.5x | XXX | XXX | XXX |
| P/E | -31.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 15.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAdimmune's NTM/LTM revenue growth is n/a
Adimmune's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $43K for the same period.
Over next 12 months, Adimmune's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Adimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Adimmune and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -5% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -84% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $43K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adimmune acquired XXX companies to date.
Last acquisition by Adimmune was XXXXXXXX, XXXXX XXXXX XXXXXX . Adimmune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Adimmune founded? | Adimmune was founded in 1965. |
| Where is Adimmune headquartered? | Adimmune is headquartered in Taiwan. |
| How many employees does Adimmune have? | As of today, Adimmune has 527 employees. |
| Who is the CEO of Adimmune? | Adimmune's CEO is Mr. Chi-Hsien Chan. |
| Is Adimmune publicy listed? | Yes, Adimmune is a public company listed on TAI. |
| What is the stock symbol of Adimmune? | Adimmune trades under 4142 ticker. |
| When did Adimmune go public? | Adimmune went public in 2010. |
| Who are competitors of Adimmune? | Similar companies to Adimmune include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Adimmune? | Adimmune's current market cap is $229M |
| What is the current revenue growth of Adimmune? | Adimmune revenue growth between 2023 and 2024 was -13%. |
| Is Adimmune profitable? | Yes, Adimmune is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
